BNGO - Bionano Genomics Short-Term Debt to Capital

The Bionano Genomics, Inc. (BNGO) price chart illustrates a debt-to-equity dynamic that currently stands at 0.03. The optical genome analysis market is expanding, although slow budget adoption by medical centers is hindering expansion. The business relies on Saphyr sales, converting clients into recurring chip buyers. High margins are achieved by scaling cartridge supplies to installed laboratories.

The development of Saphyr genome mapping systems requires significant expenditures; therefore, the ratio of current liabilities to equity measures the ability of Bionano Genomics, Inc. (BNGO) to cover current loans using net assets. This metric reflects liquidity risk amid high cash burn, allowing investors to assess balance sheet resilience against cash flow gaps through the current level of short-term capital load.